Ultragenyx Pharmaceutical to Attend Key Investor Conferences
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a pioneering biopharmaceutical company based in Novato, California. The company is dedicated to the advancement and commercialization of cutting-edge therapies tailored for patients suffering from serious rare and ultra-rare genetic conditions. As part of its mission to foster engagement with the investment community, Ultragenyx has confirmed its participation in two significant upcoming investor conferences.
Citi’s Global Healthcare Conference
Details on Participation
On December 2, 2025, Eric Crombez, M.D., Chief Medical Officer of Ultragenyx, will represent the company at Citi’s 2025 Global Healthcare Conference. This event will feature a fireside chat format, allowing for an insightful discussion about the company’s initiatives and advancements in the field of rare diseases.
Annual Evercore ISI Healthcare Conference
What to Expect
The following day, December 3, 2025, Dr. Crombez will again take the stage at the 8th Annual Evercore ISI Healthcare Conference, also engaging in a fireside chat. These conferences serve as excellent opportunities for Ultragenyx to share its vision of addressing rare diseases and to inform investors about the company's ongoing projects and commitment to innovation.
Webcasts and Accessibility
For those unable to attend the live discussions, Ultragenyx will provide a detailed webcast of both fireside chats. Interested individuals can conveniently access these recordings through the company’s official website, ensuring that their stakeholders remain informed about the latest developments.
Understanding Ultragenyx’s Commitment
Ultragenyx stands out in the biopharmaceutical landscape due to its unwavering commitment to producing novel therapies specifically designed for rare and ultra-rare genetic diseases. The organization has assembled a robust and diverse portfolio that includes both approved therapies and promising product candidates. These treatments are crucial in addressing diseases that typically lack effective management options.
Expert Leadership
The leadership team at Ultragenyx comprises seasoned professionals with extensive experience in the intricacies of developing and bringing rare disease therapeutics to market. Their strategic approach focuses on achieving swift and efficient drug development cycles. This strategy is aimed at delivering safe therapies to patients promptly, underscoring the critical nature of their work.
Engaging with the Community
As part of its broader mission, Ultragenyx is deeply committed to keeping the community informed about its endeavors. The company provides ample information through various channels, including its official website, where stakeholders can learn more about ongoing projects and therapeutic developments.
Frequently Asked Questions
1. What is the focus of Ultragenyx Pharmaceutical Inc.?
Ultragenyx is committed to developing therapies for serious rare and ultra-rare genetic diseases.
2. Who will represent Ultragenyx at the investor conferences?
Dr. Eric Crombez, Chief Medical Officer, will speak at both conferences.
3. How can investors access the conference content?
Investors can access live and archived webcasts of the conferences on Ultragenyx's website.
4. Why is Ultragenyx's work important?
Ultragenyx addresses a significant unmet medical need by providing therapies where few options exist.
5. Where can I find more information about Ultragenyx?
More details can be found on the Ultragenyx official website.
